Steven E. Kern, PhD is Deputy Director of Quantitative Sciences at the Bill and Melinda Gates Foundation. The Quantitative Sciences group is focused on quantitative analysis to support program strategies for therapeutic projects that the foundation funds. This efforts extends across all therapeutic areas in which the foundation is involved including efforts for pandemic preparedness.
Prior to this, he was Global Head of Pharmacology Modeling at Novartis Pharma AG based in Basel Switzerland where he lead a team focused on providing model based drug development support to therapeutics in many disease conditions across all stages of drug development. He joined Novartis in 2010 from the University of Utah in Salt Lake City, Utah where he was Associate Professor of Pharmaceutics, Anesthesiology, and Bioengineering, and served as co-investigator for their NIH funded Pediatric Pharmacology Research Unit. He has designed, conducted, and served as a principal investigator for clinical pharmacology studies in adults and children that spanned the population from preterm infants to elderly adults.
Inaugural ICODA Forum – International COVID-19 Data Alliance
19 November 2020 at 2:00 pm
View the agenda Additional information on the breakout sessions 14:00-16:00 GMT on Thursday 19 November The COVID-19 pandemic has highlighted the need for evidence-based decision making and...